Ruxolitinib Cream: Topical JAK Inhibitor

Overview / Definition Ruxolitinib cream is a topical medication that inhibits Janus kinase (JAK) enzymes, specifically JAK1 and JAK2. It is primarily indicated for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 years and older. By targeting the JAK-STAT signaling pathway, Ruxolitinib cream modulates the immune response, resulting in reduced inflammation and improved skin barrier function. Epidemiology Atopic dermatitis (AD) is a common inflammatory skin condition affecting approximately 10-20% of children and 1-3% of adults globally. The prevalence of AD has been increasing, particularly in developed countries. Ruxolitinib cream offers a new therapeutic option, especially for those with inadequate response to conventional treatments. Pathophysiology / Mechanism The pathophysiology of atopic dermatitis involves a complex interplay between genetic predisposition, environmental factors, and immune dysregulation. Key features include: Impaired skin barrier function: Mutations in the filaggrin gene lead to increased transepidermal water loss. Immune dysregulation: Th2-skewed immune response with elevated levels of interleukin (IL)-4, IL-13, and IL-31. JAK inhibition: Ruxolitinib cream inhibits JAK1 and JAK2, reducing the signaling of these inflammatory cytokines, leading to decreased inflammation and pruritus. Clinical Presentation Patients with atopic dermatitis may present with: Erythematous patches: Commonly on flexural areas (i.e., elbows, knees). Pruritus: Intense itching often exacerbated at night. Lichenification: Thickened skin due to chronic scratching. Secondary infections: Increased risk of Staphylococcus aureus colonization. Diagnosis / Workup The diagnosis of atopic dermatitis is primarily clinical and based on the following: History: Family history of atopy, age of onset, and symptom duration. Physical examination: Characteristic lesions and distribution. Allergy testing: May be considered in patients with suspected all